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Background: Adoptive cell therapy may be based on isolation of tumor-specific T cells, e.g. autologous tumor
infiltrating lymphocytes (TIL), in vitro activation and expansion and the reinfusion of these cells into patients upon
chemotherapy induced lymphodepletion. Together with high-dose interleukin (IL)-2 this treatment has been given
to patients with advanced malignant melanoma and impressive response rates but also significant IL-2 associated
toxicity have been observed. Here we present data from a feasibility study at a Danish Translational Research Center
using TIL adoptive transfer in combination with low-dose subcutaneous IL-2 injections.
Methods: This is a pilot trial (ClinicalTrials.gov identifier: NCT00937625) including patients with metastatic
melanoma, PS ≤1, age <70, measurable and progressive disease and no involvement of the central nervous system.
Six patients were treated with lymphodepleting chemotherapy, TIL infusion, and 14 days of subcutaneous low-dose
IL-2 injections, 2 MIU/day.
Results: Low-dose IL-2 considerably decreased the treatment related toxicity with no grade 3–4 IL-2 related
adverse events. Objective clinical responses were seen in 2 of 6 treated patients with ongoing complete responses
(30+ and 10+ months), 2 patients had stable disease (4 and 5 months) and 2 patients progressed shortly after
treatment. Tumor-reactivity of the infused cells and peripheral lymphocytes before and after therapy were analyzed.
Absolute number of tumor specific T cells in the infusion product tended to correlate with clinical response and
also, an induction of peripheral tumor reactive T cells was observed for 1 patient in complete remission.
Conclusion: Complete and durable responses were induced after treatment with adoptive cell therapy in
combination with low-dose IL-2 which significantly decreased toxicity of this therapy.
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The incidence of malignant melanoma is increasing and
every year more than 68.000 Americans will be diag-
nosed with this disease [1]. Most patients are cured after
resection of the primary tumor but for approximately
15% the disease will metastasize. Once disseminated,
malignant melanoma has a very poor prognosis with a* Correspondence: imsv@regionh.dk
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reproduction in any medium, provided the or5-year survival rate of less than 15% [1]. Chemotherapy
and radiotherapy have limited efficacy, and treatments
with curable potential have been restricted to Interleu-
kin(IL)-2 and Interferon(IFN)-α which has high toxicity,
and low response rates. Recently, several new treatment
modalities have been approved for the treatment of
metastatic melanoma. This includes the anti-CTLA-4
antibody, Ipilimumab [2,3] and the B-RAF inhibitor,
Vemurafenib [4], along with new drugs in the pipeline,
e.g. PD-1 antibodies [5,6] and MEK-inhibitors [7]. Still, a
large majority of the patients will eventually progress onl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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modalities with curable potential.
Adoptive cell therapy (ACT) with tumor infiltrating
lymphocytes (TILs) was pioneered by Rosenberg and co-
workers and has shown very promising results with high
response rates and long-term survivors [8-10]. Despite
this, the treatment has only been applied in a few cen-
ters around the world. The complicated procedure of
establishing and expanding TIL cultures is one reason
but also the toxicity of high-dose IL-2 limits the imple-
mentation of this therapy. IL-2 is administered to sup-
port further proliferation and persistency of the
transferred T cells but whether high doses of IL-2 is
required for induction of clinical response is not known.
In a previous study [11], varying doses of IL-2 were
administered together with antigen-specific T cells, but
the optimal dose of IL-2 administered with TILs remains
to be determined.
This pilot study was designed to investigate the feasi-
bility of ACT using low-dose subcutaneous IL-2 in-
jections instead of high dose intravenous IL-2. The
objectives were to examine the toxicity profile, to evalu-
ate the possibility of inducing complete and long-lasting
clinical responses and to investigate potential immune
parameters. Results from this trial, including safety




Patients between ages of 18–70 years with metastatic
malignant melanoma were included. Further inclusion
parameters were disease in progression (according to re-
sponse evaluation criteria in solid tumors (RECIST)),
measurable disease according to RECIST, at least one re-
sectable metastasis at a minimum of 1 cm3, and per-
formance status (PS) ≤ 1. Furthermore, patients had to
be seropositive for EBV antigen and negative for hepa-
titis B and C infection and HIV. Exclusion criteria were
significant heart or lung disease, autoimmune disease,
other neoplastic tumors within the last 5 years, treat-
ment with steroids, or involvement of the central ner-
vous system.
All patients signed a written informed consent before
entering the study.
Treatment and trial design
The trial was approved by the medical agencies, the eth-
ical committees and the data agency, and was conducted
in accordance with the Helsinki declaration and good
clinical practice as described by Danish law (Clinical-
Trials.gov ID: NCT00937625).
Patients were admitted to hospital at day −8 and a
central venous catheter was applied. A lymphodepletingchemotherapy regimen consisting of Cyclophosphamide,
60 mg/kg/d day −7 to −6 and fludarabine phosphate,
25 mg/m2/d at day −5 to −1 administered as previously
described [10]. Prophylactic antiemetics with palonose-
tron, aprepitant, and Domperidone were given together
with pantoprazole. At day 0 autologous TILs were
infused intravenously followed by 14 days of subcutane-
ous IL-2 injections, 2 MIU, starting the same evening.
Patients were treated prophylactically with trimetho-
prim, sulfamethoxazole, and acyclovir from the begin-
ning of treatment and 6 months thereafter and with
fluconazole during the leucopenic period.
Clinical response was monitored with a computed
tomography (CT) or positron emission tomography
(PET)/CT scan 8 weeks after T cell infusion and assessed
according to RECIST 1.0. All scans were reviewed by an
independent radiologist at the Hospital who was blinded
to previous descriptions.TIL culturing and expansion
Tumor material was obtained by excision of subcutane-
ous nodules (5 patients) or lymph nodes (6 patients).
The tumor specimen was excised aseptically and trans-
ported in AIM-V (Invitrogen, Nærum, Denmark) media
containing Fungizone. The TIL culturing method has
been adapted from Dudley et al. [12] and has previously
been described [13]. Briefly, the tumor sample were cut
into 1–2 mm fragments and placed in 24 well-culture
plates (Nunc, Roskilde, Denmark) together with 2 ml of
culture medium (90% RPMI 1640 (Invitrogen), 10% heat
inactivated Human AB serum (Sigma-Albricht, St. Louis,
MO, USA), IL-2 6000 IU/ml (Aldesleukin, Novartis,
Basel, Suisse), penicillin, streptomycin and fungi zone
(Bristol-Myers Squibb, Lyngby, Denmark). Cells were
split into 2–3 wells when cell concentration in 1 well
exceeded 1.5 x 106 cells/ml. Each fragment and the fol-
lowing TIL cultures were kept separate during further
expansion. Cell counting and viability testing were
stained with tryphan blue and analyzed by microscopy.
TIL cultures with 90% viability and more than 60 x 106
cells were frozen or transferred for further expansion in
the rapid expansion protocol (REP). Sterility testing and
microbiological control were performed on all TIL cul-
tures before freezing or expansion.
TIL bulk cultures were selected for rapid expansion
based on proliferative capacity (the fastest growing cul-
tures) and the highest percentage of CD3+, CD45RO+,
CCR7+/− and CD8+ phenotypic markers. TILs were co-
cultured with allogeneic irradiated peripheral blood
monocytes (PBMCs) serving as feeder cells together with
culture medium AIM-V, anti-CD3 antibody (OKT-3,
Cilag AG, Suisse), and IL-2 in upright T175 flasks. At
day 14 the expansion rate had increased by more than
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the lymphodepleted patient.Immunological assays
Fluorochrome-conjugated antibodies for flow cytome-
try were the following: CD3, CD4, CD8, CD27,
CD45RO, CCR7, IFN-γ, TNF-α, and CD107a (BD,
Brøndby, Denmark).
The infusion product and PBMCs obtained before and
after treatment from each patient were tested for reactiv-
ity against short-term cultured autologous melanoma
cell lines (when available), generated from the same spe-
cimen used for TIL generation by serial passage of ad-
herent cells [14], or against a panel of 4 to 8 HLA-A
matched allogeneic melanoma cell lines. In addition, in-
fusion products were also tested for reactivity against a
panel of tumor-derived peptides. The following techni-
ques have been applied.Intracellular cytokine staining (ICS)
A flow cytometry-based assay was performed in order to
depict the production of cytokines when cells from the in-
fusion product were co-cultured with 1) tumor cell lines, as
previously described [14] or with 2) mRNA-transfected au-
tologous DCs: 1) Co-culture with tumor cell lines: TILs
were cultured for 5 hours at 37°C with 5% CO2 in air in the
presence or absence of melanoma cells at an effector/target
ratio of 3:1. 2) Co-culture with mRNA-transfected autolo-
gous DCs: One patient (patient 11) had previously been
included in a clinical phase I protocol at our center (Clini-
calTrials.gov ID: NCT00978913) in which DCs transfected
with mRNA encoding p53, survivin or hTERT were evalu-
ated in patients with metastatic breast cancer or malignant
melanoma (Additional file 1). TILs from this patient were
cultured for 5 hours with i) the DC-vaccine, ii) autologous
DCs transfected with p53, survivin and hTERT mRNA, iii)
autologous DCs transfected with single mRNA and iv) au-
tologous DCs transfected with mock mRNA (i.e. negative
control) at an effector/target ratio of 10:1. Staphylococcal
Enterotoxin B (SEB) (Sigma-Aldrich, 5 μg/ml final concen-
tration) was used as positive control. In selected analyses
anti-CD107a (BD, 0.03 ug/ml final concentration) was
added at the beginning of the incubation. GolgiPlug
(Sigma-Aldrich) was added at a dilution of 1:1000 after the
first hour of incubation. After 4 additional hours cells were
washed twice with PBS, stained with Fixable Viability Dye
(Ebiosciences) and with antibodies directed to surface mar-
kers. Cells were washed one additional time, fixed over-
night, permeabilized and subsequently stained with
antibodies for intracellular cytokines. Cells were analyzed
using a BD FACSCanto II flow cytometer. At least 1 x 105
TILs or lymphocytes were acquired. Analysis was per-
formed with BD FacsDiva Software. Responding cellswere defined as those who stained double positive for
IFN-γ and TNF-α.
ELIspot assays
An IFN-γ ELIspot assay was performed to quantify the
number of TILs responding to 1) tumor-associated pep-
tides, as previously described [14,15] or to 2) mRNA
transfected autologous DCs.
Briefly, nitrocellulose bottomed 96 well plates (Multi-
screen MAIP N45, Millipore, Copenhagen, Denmark)
were coated with IFN-γ capture antibody (1-DIK, Mab-
tech, Nacka Strand, Sweden). The wells were washed,
blocked with X-VIVO 15 medium and TILs were added in
triplicates at different cell concentrations. 1) TILs respond-
ing to tumor-associated peptides: TILs were cultured for
4 hours at 37°C with 5% CO2 in air with or without
tumor-associated peptides (final concentration 5μM). 2)
TILs responding to mRNA-transfected autologous DCs:
TILs were cultured for 4 hours at 37°C with 5% CO2 in air
with i) the DC-vaccine, ii) autologous DCs transfected
with p53, survivin and hTERT mRNA, iii) autologous DCs
transfected with single mRNA and iv) autologous DCs
transfected with mock mRNA (i.e. negative control). After
addition of secondary biotinylated antibody (7-B6-1-Bio-
tin, Mabtech) and Streptavidin-enzyme conjugates (Strep-
tavidin-ALP, Mabtech), the enzyme substrate nitro blue
tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (NBT/
BCIP, Mabtech) was added to each well and the reactions
were stopped with tap water. Spots were counted with the
ImmunoSpot Series 2.0 Analyzer (CTL Analyzers). A
positive response was defined as more than twice the
background and at least 50 spots/well.
MHC-multimer staining
To screen for reactivity against a large panel of melan-
oma associated peptides we used flow cytometry based
detection of MHC multimer binding T cells by a com-
binatorial encoding technique [16].
Peptides were purchased from Pepscan (Pepscan Presto
BV, Lelystad, Netherlands) and dissolved to 10 mM in
DMSO. Recombinant MHC heavy chains and β2microglo-
bulin light chain were produced in Escherichia coli and
refolded with conditional ligands, as described by Hadrup
et al. [17]. Specific peptide-MHC complexes were pro-
duced by UV-mediated peptide exchange of conditional
ligands [17,18]. The conditional ligands were synthesized
as previously described [18-20]. MHC multimers were
generated using 8 different streptavidin (SA)-fluoro-
chrome conjugates (SA-PE, SA-APC, SA-PE-Cy7 (BioLe-
gend, San Diego, CA, USA), SA-quantum dot (Qdot)585,
SA-Qdot605, SA-Qdot625, SA-Qdot655 and SA-Qdot705
(Invitrogen)). Each peptide-MHC multimer was generated
in two different colors, which allows a two-color coding
upon staining of specific T cells, as described [16]. This
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tional. These are used for staining of 27 T cell populations
in 1 sample. Eight panels were prepared for analysis of
175 melanoma-associated T cell epitopes (10 HLA-A1,
146 HLA-A2, 11 HLA-A3, 3 HLA-A11 and 5 HLA-B7
epitopes) [21]. Eighteen virus-derived T cell epitopes were
included as positive control of the method.
All T cell stainings were performed on cryopreserved
material. Up to 106 cells per sample were stained with 1
MHC multimer panel for 15 min at 37°C and 5% CO2.
Next, cells were stained with anti-CD8-Alexa Fluor 700
(Biolegend), dump channel antibodies (CD4-, CD14-,
CD16-, CD19-FITC (BD) and CD40-FITC (AbD Sero-
Tec, Oxford, UK)) and a dead cell marker (LIVE/DEAD
Fixable Near-IR, Invitrogen) for 30 min on ice. Final
staining volume was 100 μl. Subsequently, cells were
washed twice with PBS containing 2% fetal bovine serum
(FBS) and resuspended in 50 μl PBS containing 2% FBS.
Data acquisition was performed on an LSR-II flow cyt-
ometer (BD), and data analysis was carried out using
FACSDiva software (BD). Responses were defined as a
minimum of 10 spots and a minimum of 0.002% of
CD8+ T cells. All responses were verified in a vali-
dation screen, using different color-codes for the given
MHC multimer specificity.
Statistical analysis
Survival was defined as the time from initiation of treat-
ment until death or last date of follow-up (March 1st,
2012). Time from treatment initiation until exclusion
from the trial due to disease progression was defined as
time to progression (TTP).
Results
Patient characteristics
Eleven patients with metastatic malignant melanoma
were enrolled from June 2009 till June 2011. Six of the
11 included patients were treated according to the proto-
col. All patients were previously treated with high-dose
IL-2 according to an intravenous decrescendo regimen
previously described by Keilholz et al. [22]. Demographic
data for these 6 patients are depicted in Table 1.
From 1 of the 11 patients TIL cultures were not estab-
lished. Two patients developed large symptomatic brain
metastases during the time of TIL culturing and 2
patients had rapid disease progression after tumor resec-
tion. They were therefore excluded from the trial before
treatment initiation. Thus, 5 patients were included in
the trial and had tumor resected but were not treated.
Clinical results
Of the 6 treated patients, 2 patients achieved a complete
response (CR), 2 patients had stable disease (SD) and 2
patients progressed rapidly (Table 2).Patient 1 had a brain metastasis surgically excised prior
to inclusion in this trial. At time of inclusion the patient
had disseminated disease limited to lymph nodes in the
pelvis and 1 of these were removed for the preparation of
TILs. Because of post-surgery complications with abscess
formation and a peripheral deep venous thrombosis cells
were frozen until the patient had recovered. After therapy
this patient had slow regression of the metastases leading
to a negative PET/CT scan 1½years after treatment. This
patient is continuously in complete remission 30 months
after treatment.
Patient 11 was initially included in a dendritic cell vac-
cination protocol but because of large metastases on the
neck and cheek the patient underwent palliative plastic
surgery. Tumor material was sent to the laboratory and
TIL cultures were established and frozen for later use.
Four months later the patient progressed on the initial
treatment and was subsequently included in this proto-
col. Eight weeks after T-cell infusion there were no sign
of disease and previous PET-positive lesions were nega-
tive (Figure 1b). This patient is in ongoing complete re-
mission 10 months after therapy.
Patient 3 had SD on the 1st evaluation scan but 4 months
after T-cell therapy an increase in tumor burden of 26%
led to exclusion from the protocol. Also patient 7 had SD
but developed a new metastasis 5 months after therapy
and was therefore excluded due to progressive disease
(PD). Patient 2 and 5 had PD at 1st evaluation 8 weeks
after therapy.
In total, the 6 patients have a median TTP of 8.2 months
(range 2–30 months) and an overall survival (OS) of
12 months (range 5–30 months) with 2 ongoing complete
responses (Table 2).Toxicity
In general, toxicity grade 3–4 (according to Common Ter-
minology Criteria for Adverse Events (CTCAE) v. 3.0) was
related to the lymphodepleting chemotherapy with gastro-
intestinal symptoms, fatigue and low blood cell counts. All
patients had a grade 2 anemia and received blood transfu-
sions, 1 patient had thrombocytopenia and received plate-
let transfusions and all patients had grade 4 leucopenia,
neutropenia and lymphopenia (Table 3).
Notably, very low sodium levels were observed in the
first patients during administration of Cyclophospha-
mide. We found that restriction of oral water intake dur-
ing infusion of Cyclophosphamide could control the
sodium level in the following patients.
The infusion of TILs led to fever and chills for most of
the patients. Two patients reacted to the infusion of
TILs with high blood pressure and tachycardia. Symp-
toms were treated with morphine, antihistamines and
oxygen and relieved after a few minutes.
Table 1 Patient demographics
Patient
number
Age(years) Sex HLA- type PS Previous treatments Tumor burden (cm) AJCC stage Metastatic sites
1 60 F A2 0 IL2/INF, brain surgery 3.9 M1c LN, braina
2 47 M A2/A3 0 IL2/IFN, DC-vac, abdominal surgery 22.8 M1c LN, intestines
3 62 M A3/A11 0 IL2/IFN, DC-vac 15.5 M1c SC, lung, stomach, gall bladder
6 36 M A2 0 IL2/IFN 8.6 M1c LN, liver, bone
7 61 M A2/A24 0 IL2/INF, CD137, DC-vac, brain surgery 19.8 M1c LN, lung, bone, braina
11 41 M A1/A3 0 IL2/INF, Ipilimumab, DC-vac 3.5 M1a LN, SC
PS: performance status, AJCC: American Joint Committee on Cancer, M:male, F:female, IL2/INF:Interleukin-2/Interferon-α (according to the treatment regimen
described by Keilholz et al. ref. 20), DC-vac: dendritic cell vaccine (experimental treatment), CD137:CD137 antibody (experimental treatment), LN: lymphnode
metastasis, SC: subcutaneuous metastasis. Tumor burden was defined as the sum of all measurable lesions (>1 cm in longest diameter) up to a maximum of 10
lesions (according to RECIST 1.0). aBrain metastases were surgically removed before inclusion in the protocol.
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tions without dose reductions were given. As expected,
patients developed fever during treatment with IL-2 injec-
tions and were consequently treated with antibiotics.
Other side effects were chills a few hours after injection,
nausea and fatigue, although none of these exceeded grade
2 toxicity. Nausea and fatigue were assessed to be related
to the previously administered chemotherapy.TIL characteristics
Approximately 18 cultures were initiated from each pa-
tient and 3–5 of these gave rise to a culture with suffi-
cient growth for further expansion. REP was started at
an average cell count of 18 x 106 (range 11–30 x 106)
cells after a mean time of 32.5 days (range 24–42 days)
in culture. In average 26 x 109 (range 3.4 – 74.7 x 109)
TILs were infused in each patient (Table 2).Table 2 Treatment characteristics and clinical outcome





CD8+ CD45RO+ CCR7+ CD27+
(x 1010) (%) (%) (%) (% of CD8)
1 2.9 94 99.7 7.5 6.1
2 1.8 92 97.4 4.9 5.2
3 2.0 95 99.4 6.1 0.5
6 0.3 47 98.4 3.9 1.2
7 1.3 88 89 31.8 3.4
11 7.5 95 99 0.6 8.1
Table showing phenotypic and functional characteristics of the infusion products as
aReactivity meaning tumor-specific CD8+ T cells in % of infused TILs. Reactivity wa
CD8+ T cells expressing TNF-α and IFN-γ after co-culture with *autologous tumor
several allogeneic melanoma cell lines reactivity against the cell line that resulted
Additional file 2). RECIST: Response Evaluation Criteria in Solid Tumors, TTP: time t
SD: stable disease, PD: progressive disease.Phenotype of the infused cells showed that the majority
of cells were effector memory T cells expressing (CD3
(97-100%) and CD45RO (89-100%) and low expression of
CCR7 (0.6-32%)). The percentage of CD8 T cells ranged
from 47-95%, and between 0.5-8.1% of the CD8 cells were
CD27 positive (Table 2).
Reactivity of the infusion products was tested using
several different techniques; including ICS, IFN-γ ELI-
spot assay and MHC multimer staining.
Infused T cells were tested for production of different
cytokines (TNF-α and IFN-γ) when co-cultured with
autologous melanoma cell lines (2 patients) or a panel
of HLA-A matched allogeneic cell lines (4 patients)
(Additional file 2). Reactivity of the TILs against autolo-
gous tumor from patient 11 is depicted in Figure 1a,
upper row. The 2 clinical responding patients (patient 11
tested against an autologous cell line and patient 1 tested
against an allogeneic cell line) had higher reactivity thanusion products Clinical outcome




(%) (x 106) (RECIST) (mo) (mo)
28.8# 6460 CR 30+ 30+
1.0# 175 PD 2 7
0.0# 7 SD 4 11.5
0.9* 41 PD 2 4.6
0.4# 44 SD 5 11
6.0* 4377 CR 10+ 10+
well as clinical outcome for the 6 treated patients.
s calculated by intracellular cytokine staining measuring the percentage of
cell lines or #allogeneic melanoma cell lines. For patients tested against
in the highest reactivity has been shown (for further details please see
o progression, OS: overall survival, mo: months, CR: complete response,
Table 3 Toxicity
Grade 1 Grade 2 Grade 3 Grade 4
Performance status 1 4 1













Low sodium levels 2 3 1
No grade 3–4 events were associated with Interleukin-2 treatment. Grade is
referring to Common Terminology Criteria for Adverse Events (CTCAE) v. 3.0.
Digits in the table are referring to number of patients with the given
adverse event.
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more than 80 fold higher absolute number of tumor-
specific CD8+ cells in the infusion product was observed
among the 2 responding patients compared to the 4 non-
responders (5418 x 106 vs. 67 x 106 CD8+ T cells (mean
values)) (Table 2). Reactivity against the tumor cell lines
were confirmed for the 2 responding patients by direct
IFN-γ ELIspot analyses (data not shown).
Reactivity against a selected panel of peptide epitopes
from well-characterized melanoma antigens was tested with
direct IFN-γ ELIspot analyses (Table 4a). In these analyses
we found reactivity against 23-60% of the tested peptides.
In addition, we tested for the presence of CD8 T cells rec-
ognizing a large panel of 173 peptides, representing all pub-
lished epitopes of relevance for melanoma (the full peptide
list can be found in Andersen RS et al. [21]). To screen for
reactivity against this large panel of melanoma associated
peptides a combinatorial encoding technique was applied
[16] (Examples of MHC multimer stainings have been pre-
sented in Additional file 3). Using this technique, we con-
firmed only 3 of the responses detected by ELIspot and
detected another 8 responses towards a limited set of pep-
tides from this large peptide library (Table 4b). Most of the
T cell responses detected were of low frequency, in con-
cordance with previous published data [21,23], and even
this large peptide library is limited in describing the
epitope-specificity of the autologous and allogeneic tumor
cell recognition observed. There were no correlation be-
tween peptide specific reactivity and clinical response.Immune monitoring
PBMCs from before and after treatment were tested by
ICS for reactivity against autologous tumor cell lines
when available (patient 11), otherwise the allogeneic
melanoma cell lines against which the infusion product
had shown highest reactivity were used (patient 1, 2, 3
and 7). No increase in baseline reactivity was seen, ex-
cept for patient 11 who had no activity when tested at
baseline but developed a response 1 week after T cell in-
fusion which was confirmed after 3 weeks (Figure 1a).
This patient had a complete clinical response to the
treatment (Figure 1b).
Re-activation of previously activated T cells from a
patient treated with a dendritic cell (DC) vaccination
One patient (patient 11) had previously been included in
a clinical phase I trial where DCs transfected with
mRNA encoding p53, survivin or hTERT were evaluated
in patients with metastatic breast cancer or malignant
melanoma (Engell-Noerregaard et al. trial ongoing, see
Additional file 1 for further information). Accordingly,
we questioned whether the infusion product could elicit
immune responses to the mRNA transfected DC-vac-
cine. For this purpose, TILs from patient 11 were stimu-
lated with either the DC-vaccine or DCs transfected
with triple mRNA and vaccine-specific TILs were subse-
quently analyzed with ELIspot IFN-γ release assay and
ICS. Using this approach, we were able to detect IFN-γ
TIL reactivity against the DC-vaccine and transfected
DCs in both the ELIspot and ICS assay (Figure 2). Fur-
ther analysis using single mRNA-transfected DCs as tar-
get revealed that the TIL response was predominantly
against hTERT-transfected DCs (Figure 2a). This was
consistent with the responding TILs detected using the
ICS assay (Figure 2b). No response was detected when
TILs were stimulated with p53, survivin or mock-
transfected DCs (Figure 2).
Discussion
Herein we report the results from 6 patients treated with
lymphodepleting chemotherapy, autologous TILs and
very low-doses of IL-2. This trial shows that it is possible
to induce complete and long-lasting responses even with
the use of low-dose IL-2 that significantly reduced the
toxicity of therapy. Today, ACT is only implemented in
few clinical centers, but if high-dose IL-2 was not
required, it could be possible to offer this therapy
more widely and to more patients. With this said, this
is a pilot trial including only 6 patients, and whether
the doses of IL-2 affects the clinical response rate war-
rants further study. Thus, larger clinical studies are
needed to confirm whether high response rates can be

























Figure 1 Immune and clinical evaluation of patient 11. a) FACS plot from intracellular cytokine staining showing the percentage of interferon
(IFN)-γ and tumor necrosis factor (TNF)-α producing CD3+CD8+T cells after incubation with autologous tumor cell lines or Staphylococcal
Enterotoxin B (control). First row showing reactivity of tumor infiltrating lymphocytes (TIL) from the infusion product, second and third row
showing reactivity of peripheral blood monocytes (PBMC) 1 week before infusion of TILs and 3 weeks after. b) PET/CT scan from 1 week before
infusion of TILs and 8 weeks after infusion of TILs. Arrows outlining the measurable disease.
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setting have been performed by others. Yee et al. [24]
demonstrated that adoptively transferred T cell clones
targeting melanoma-associated antigens could persist
in vivo in response to very low doses of IL-2. Two other
groups [25,26] have shown that Melan-A-specific CD8+
T cells were able to induce long-lasting responses in
metastatic melanoma patients and that transferred cells
persisted and even expanded in vivo. In these studies the
infusion of T cells was followed by subcutaneous injec-
tions of low-dose IL-2 and/or IFN-α suggesting that
low-doses of cytokines might well be sufficient to pro-
long survival of the transferred cells and induce object-
ive clinical responses. This is further underlined by the
results from Verdegaal et al. [27] who reported on a
clinical study transferring blood derived tumor-specific
T- cells into metastatic melanoma patients in combin-
ation with low-dose IFN-α still observing long lasting
clinical responses. A recently published retrospective re-
port from Ullenhag and colleagues [28] described a co-
hort of patients treated with ACT and a low dose IL-2
regimen with 2.4 MIU/m2 once a day continuing untilprogression. Long lasting response in 1 of the patients
was reported; however, continuous treatment with IL-2,
even in low-doses, might significantly interfere with
quality of life for those patients achieving durable
responses. Besides, it is questionable whether long-term
IL-2 treatment is necessary for continuous tumor con-
trol [8,9].
Only 6 of 11 included patients who underwent tumor
resection with the intent to treat actually received treat-
ment. In this study, patients were treated with TILs from
selected individual cultures resulting in a culturing time
(including REP) of about 7–8 weeks. Treating patients
with unselected young TILs can decrease the production
time to 4–5 weeks [8,29]. Also, the use of engineered cells
for costimulatory enhancement during TIL expansion has
been described to accelerate TIL growth [30] and hereby
decrease the time from surgery to treatment. Accelerated
preparation time might reduce the drop-out rate, as 4 out
of 5 patients who were not treated in this trial were
excluded due to deterioration of performance and/or the
appearance of brain metastases awaiting the treatment.
Furthermore, methods to improve the reliability of TIL
Table 4 T-cell responses detected in TIL infusion products
a) IFN-γ ELIspot analyses
Patient ID 1 2 3 6 7 11
HLA-type A2 A2/A3 A3, A11 A2 A2 A1, A3
A2 Bcl-2WLD NR 43 - NR 301 -
Bcl-xRIA NR 165 - NR 197 -
hTERTILA 180 456 - 363 462 -
CB9L2ALY 232 135 - 293 441 -
CB9 204ILI 488 502 - 325 408 -
NY-ESO 1SLL 180 564 - 158 279 -
MAGE A1KVL NR 57 - NR 190 -
MAGE A3FLW 91 67 - 118 250 -
SUR1M2LML ND 96 - ND 349 -
SUR9ELT ND 62 - ND 274 -
MART-1ELA ND 324* - 193* NR -
gp100ITD ND 106 - ND ND -
A3 Bcl-xRIA - 284 111 - - 59
SUR18K10RIS - ND 112 - - NR
SUR53DLA - 96 ND - - 82
Rho C (nat)RAG - ND 114 - - NR
Rho C (mod)RLG - ND 103 - - NR
TAGRLS - ND ND - - 42*
Number of responses/total screened 5/15 14/24 4/9 6/15 9/15 3/13
Background 99 46 86 130a/92b 131 29
b) MHC multimer staining
Patient ID 1 2c 3 6 7 11d
HLA-type A2 A2, A3, B7 A3, A11 A2 A2 A1, A3
A2 MART-1ELA 0.013 0.07* - 1.10* 0.008 -
gp100YLE 0.010 NR - 10.0 NR -
gp100KTW 0.010 NR - NR -
gp100ITD 0.002 NR - 0.018 NR -
GnT-VVLP-9 0.015 NR - NR NR -
A3 TAGRLS - NR NR - - 0.60*
Number of responses/total screened 5/146 1/162 0/14 3/146 1/146 1/21
a) IFN-γ ELIspot analyses; Responses are defined as number of spots per 1 x 105 T cells, except for patient 7 (2.5 x 104 cells) and patient 11 (1.25 x 104 cells).
Background level shown at the bottom of the table has been subtracted in the shown responses. a/b: two different assays have been performed wherefore two
background values are present.
b) MHC multimer staining; Antigen-specific T cells are given in percentage of CD8+ T cells. Examples of MHC multimer stainings can be seen in Additional file 3.
cThe TILs analyzed were frozen two days after infusion. dThe TILs analyzed were frozen one day after infusion.
Last row indicates the number of detected responses out of the total number of peptides screened. NR: no reactivity, ND: reactivity testing not done, -: not tested
due to HLA-discrepancy.
*Indicating responses found in both methods. nat: natural, mod: modified.
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number of patients not treated due to insufficient TIL
growth [30,31]. Validation and implementation of these
processes will reveal if this can further increase the frac-
tion of treated patients.
The infusion product for each patient was tested for
reactivity against a large panel of melanoma antigens.
Screening for reactivity against different peptides showedsome responses but these were unable to fully explain
the anti-tumor reactivity observed. The limited peptide
reactivity is in line with recent data, showing recognition
of only a small fraction of the described melanoma-
associated peptides and predominantly very low
frequency of antigen specific T cell populations [23,32].
Furthermore, only few of the responses detected by















































































Figure 2 Infusion product tested for reactivity against a dendritic cell vaccine (patient 11). a) IFN-γ ELIspot analyses; Responses are defined
as number of IFN-γ secreting cells per 3 x 103 TILs. b) Intracellular cytokine staining; percentage of T cells staining double positive for IFN-γ and
TNF-α (first column) or for CD8 and CD107a (second column) DC-mock: mock-transfected dendritic cell (negative control), vac: vaccine, tri: triple
transfected, sur: survivin, hTERT: human Telomerase Reverse Transciptase, TIL: tumor infiltrating lymphocytes.
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part of this discrepancy relies to the fact that the major-
ity of the “self-reactive” T cells posses a very low affinity
to the MHC possibly insufficient for MHC-multimer
binding, but sufficient for stimulation of IFN-γ secretion
upon addition of excess amounts of peptide. In addition,
a number of reports have shown that IFN-γ secretion
after stimulation with short peptides may result from
CD4 T cells (Eckhart Kämpgen, Erlangen, Germany,
personal communication), and the performed IFN-γ
ELIspot analyses did not discriminate between CD4
and CD8. Nevertheless, the TIL infusion product con-
sisted of mostly CD8 T cells (Table 2) wherefore this
would be able to explain only a limited part of the dif-
ferences in reactivity.
Conclusions on correlation between clinical response
and patient demographics or treatment characteristics
are not possible with 6 treated patients. However, the 2
responding patients’ characteristics differ from the non-
responding patients. Both responding patients had gone
through extensive surgery and had, at the time of treat-
ment initiation, only limited disease burden, suggestingthat debulking of tumor-mass may play a role for the
outcome of TIL therapy using low-dose IL-2. Also, a
high percentage of CD8 T cells and a high number of
infused TILs were characteristic for the responding
patients (Table 2). Even though several patients, includ-
ing non-responding patients had a high percentage of
CD8 T cells in the infusion product this might, together
with other factors such as high reactivity against melan-
oma cell lines, increase the possibility of obtaining a
clinical response. Interestingly, we found that a high ab-
solute number of tumor-reactive T cells in the infusion
product were more than 80 times higher for patients
with a clinical response than for non-responders.
Correlations between clinical response and patient
demographics or treatment characteristics have been in-
tensively investigated by others. In ACT trials using high
dose IL-2 no correlation between tumor burden and clin-
ical response has been observed previously [9] and
whether our findings are due to the lower amount of
IL-2 given or whether it might just be a coincidence con-
sidering the low number of patients treated can not be
concluded in this pilot study. Besser et al. [8] also found
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the infusion product and clinical response as well as be-
tween the number of infused cells and clinical response.
Longer telomer length, a high percentage of CD8+CD27+
TILs and persistency of the infused cells in the circula-
tion have also been shown to correlate with clinical re-
sponse [33] wherefore new methods resulting in shorter
culturing time (young TILs) has emerged [8].
Future initiatives on how to increase the tumor-
reactivity of infused TILs should be considered. We have
recently shown that IFN-γ is able to increase the im-
munogenicity of melanoma cells thereby restoring the
responsiveness in otherwise unresponsive T cells in clin-
ical TIL products (Donia M et al. accepted for publica-
tion, J Invest Dermatol, 2012) and IFN-α has in a
previous study been shown to be able to induce clinical
responses in combination with ACT [27]. Also, other
agents, such as BRAF inhibitors have been shown to
have immune modulating potential [34-36]. Thus, the
use of these agents in combination with ACT could have
the potential to enhance immunogenicity of tumor cells
and thereby increase the fraction of tumor-specific T
cells in the TIL product capable of killing tumor cells.
A high percentage of vaccine-specific T cells were found
in the infusion product from a patient previously treated
with an mRNA transfected DC vaccine. We hypothesize
that vaccine-specific T cells were induced during the DC
vaccination but were not able to overcome immunosup-
pressive mechanisms and therefore did not give rise to a
clinical significant anti-tumor response. When T cells
were activated and expanded ex-vivo and re-infused into
the lymphodepleted patient a clinical response could be
established. Further analyses will be performed to clarify
whether the vaccine-specific cells are indeed induced dur-
ing vaccination and whether these cells equal the tumor
reacting cells.
Conclusions
In conclusion, we demonstrate that durable complete
responses can be achieved using ACT and short duration
of low-dose IL-2. The much less toxic regimen simpli-
fies the clinical setting of this therapy making it more
attractive for other centers to establish. Also, the pos-
sibility of an association between the absolute num-
ber of tumor-reactive T cells infused and clinical
response is shown. This knowledge could be used in
the future search for optimizing ACT, with new trials
focusing on increasing the tumor-sensitivity to T cell
mediated killing as well as the number of potent
tumor-reactive T cells.
Our findings of cancer vaccine-specific T cells in the
infusion product from a patient who subsequently
achieved complete response support the idea of inducing
anti-tumor T cells by a cancer vaccine. The techniquefor subsequent expansion in vitro have been established
in a preclinical setting [37] and will be incorporated in a
clinical trial initiated in the near future. Also, we have
initiated a new trial for metastatic melanoma patients
using young-TIL ACT in combination with intermediate
doses of IL-2 (ClinicalTrials.gov ID: NCT00937625) with
the purpose of defining the most optimal dose of IL-2
for the use in a larger randomized clinical trial.
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